{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-014430","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.371006+00:00","generated_at":"2026-06-23T09:29:40.112730+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Xilio appoints Tomas Heyman to Board of Directors","bullets":["Tomas Heyman appointed as Class I director effective September 15, 2022.","He will serve until the 2025 annual meeting or until earlier resignation.","Appointed to Nominating and Corporate Governance Committee and Audit Committee.","Compensation follows standard non-employee director arrangements as disclosed in 2022 proxy statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-014430","json":"https://secwatch.observer/filing/0001558370-22-014430.json","markdown":"https://secwatch.observer/filing/0001558370-22-014430.md","text":"https://secwatch.observer/filing/0001558370-22-014430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/xlo-20220915x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:29:40.112730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca114c6888","claim":"Tomas Heyman was appointed as Class I director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective September 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tomas Heyman to the Board as a Class I director of the Company, to serve in such capacity until the Company’s 2025 annual meeting of stockholders or until his earlier resignation, death, or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}